NCT03881488 - Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

May 17, 2019

Primary Completion Date

May 21, 2025

Study Completion Date

May 21, 2025

Conditions

Locally Advanced Solid TumorMetastatic CancerNon-small Cell Lung CancerSmall Cell Lung CancerMesotheliomaMelanomaHead and Neck Cancer

Interventions

DRUG

CTX-471

IV infusion every 2 weeks

DRUG

Pembrolizumab (KEYTRUDA®)

IV infusion every 6 weeks

Trial Locations (10)

Mt Sinai, New York

Duke University School of Medicine, Durham

Institute for Translational Oncology Research (ITOR), Greenville

Ocala Oncology Center, Ocala

Hematology Oncology Associates Of The Treasure Coast, Port Saint Lucie

Washington University School of Medicine, Siteman Cancer Center, St Louis

Mary Crowley Cancer Research, Dallas

Massachusetts General Hospital, Boston

Dana-Farber Cancer Institute, Boston

Hackensack University Medical Center, Hackensack